Sakamoto, J., Ohashi, Y., Hamada, C., Buyse, M., Burzykowski, T. and Piedbois, P., Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum, Meta-Analysis Group in Cancer (2004) Efficacy of Oral Adjuvant Therapy after Resection of Colorectal Cancer: 5-Year Results from Three Randomized Trials. Journal of Clinical Oncology, 22, 484-492.

has been cited by the following article:

• TITLE: Efficacy of Postoperative Adjuvant Chemotherapy According to Prognostic Factor in Patients with Stage III Colon Cancer

  AUTHORS: Kiichi Sugimoto, Kazuhiro Sakamoto, Yuichi Tomiki, Michitoshi Goto, Yutaka Kojima, Hiromitsu Komiyama, Makoto Takahashi, Shun Ishiyama, Koichiro Niwa, Haruna Okubo

  KEYWORDS: Colorectal Cancer, Postoperative Adjuvant Chemotherapy, Prognostic Factor, Stage III Colon Cancer, TNM Classification, 7th Edition

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.8, July 21, 2014

  ABSTRACT: Background: We retrospectively identified prognostic factors in patients with Stage III colon cancer and considered the effectiveness of postoperative adjuvant chemotherapy based on these prognostic factors. Methods: Two hundred and thirty four patients with lymph node metastases who underwent curative surgery for colon cancer between 1999 and 2005 were enrolled in the present study. Firstly, clinicopathological factors and survival data, were analyzed to determine prognostic factors related to cancer-specific survival. Secondly, we examined the effectiveness of postoperative adjuvant chemotherapy based upon these prognostic factors. Results: The multivariate analysis revealed that differentiation (P = 0.03, Hazard ratio = 2.50), lymphatic invasion (P = 0.02, Hazard ratio = 3.23) and the TNM classification, 7thedition (P = 0.04, Hazard ratio = 1.94) were found to be significant independent prognostic factors. Among the patients classified as TNM IIIA, the recurrence-free survival rates were extremely good. Among the patients classified as IIIB and IIIC, there was no significant difference between the patients with and without postoperative adjuvant chemotherapy. Conclusion: The present study suggests that the patients with Stage IIIA colon cancer may not require postoperative adjuvant chemotherapy. The addition of oxaliplatin to 5-FU should be considered for the patients with Stage IIIB and IIIC colon cancer, for whom the prognoses are far from satisfactory.